Omega-3 Marketers Back Down On Comparisons To Amarin's Vascepa

Coromega Health and Omax will issue press releases explaining that the Amarin study each firm noted in previous releases was not relevant to omega-3 supplements. Releases subject to publication within three days of each settlement's finalization include six mentions of Amarin's Rx prescription triglyceride-lowering fish oil, Vascepa.

Finger Pointing_184348979_1200.jpg

The two omega-3 dietary supplement marketers Amarin Corp. PLC targeted in nearly identical false advertising complaints after they said their products provide cardiovascular health benefits similar to Amarin's Rx fish oil agree to publish nearly identical corrections.

On another litigation front, Amarin recently stumbled in its attempt to compel the International Trade Commission to block imports of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Stada Acquires Fortacell To Grow In Balkans

 
• By 

Stada's Serbian subsidiary Hemofarm has enhanced its offering in the dietary supplements category with the acquisition of Fortacell from Goodwill Pharma.

Vision Healthcare Strikes Deals To Expand European Offering

 
• By 

Belgium-based Vision Healthcare has acquired Svenskt Kosttillskott in Sweden and New Care Supplements in the Netherlands.

Over The Counter: Seizing The GLP-1 Wellness Opportunity, With Kerry Group’s Mathieu Millette

 
• By 

HBW Insight speaks to Kerry Group's RDA director for digestive health, Mathieu Millette, about the opportunity represented by the global trend for GLP-1 agonists for consumer health.

Consumers More Often Choosing Private Label First

 

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

More from Wellness

Consumers More Often Choosing Private Label First

 

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

People In US Consumer Health News: Bayer North America Treasurer Takes On CFO Role, Too

 

Bayer North America CFO with firm since 2008; Cosette VP for quality, regulatory affairs; FDA labeling review official joins ProPharma; Lifecykel, UFC veterans launch Mongolian training camp; and Beverly Hills surgeons offer skin care supplement.

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By 

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.